REGENERON PHARMACEUTICALS INC. - COMMON STOCK

75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition

16 5 2025 10:24:49 提供 Nasdaq GlobeNewswire

Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments

15 5 2025 13:02:43 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

08 5 2025 08:50:56 提供 NetDania Notify

Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination

01 5 2025 08:30:00 提供 Nasdaq GlobeNewswire

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases

01 5 2025 08:00:00 提供 Nasdaq GlobeNewswire

Regeneron Reports First Quarter 2025 Financial and Operating Results

29 4 2025 05:30:00 提供 Nasdaq GlobeNewswire

Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma

28 4 2025 06:01:41 提供 Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease

28 4 2025 06:00:32 提供 Nasdaq GlobeNewswire

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines

22 4 2025 05:00:00 提供 Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

21 4 2025 15:05:00 提供 Nasdaq GlobeNewswire

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

18 4 2025 14:00:22 提供 Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

18 4 2025 10:15:32 提供 Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications

17 4 2025 06:00:08 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

09 4 2025 08:45:11 提供 NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

08 4 2025 12:12:54 提供 NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

07 4 2025 08:45:03 提供 NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

04 4 2025 08:46:04 提供 NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

03 4 2025 15:08:52 提供 NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

02 4 2025 08:45:07 提供 NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

01 4 2025 13:45:14 提供 NetDania Notify